Valbiotis SA (FR:ALVAL) has released an update.
Valbiotis, a French research lab, has been invited to showcase their TOTUM•63 Phase II/III REVERSE-IT study results at the American Diabetes Association’s 84th Scientific Sessions, demonstrating significant efficacy in managing prediabetes and early type 2 diabetes. The study outcomes, emphasizing TOTUM•63’s ability to improve glucose homeostasis and reduce glycated hemoglobin levels, present a promising non-drug, plant-based intervention for diabetes prevention and early treatment.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.